Amgen swallows Micromet to BiTE into ALL market
Author:
- 10 April 2012
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 30 (4) , 300-301
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Engineered T-cell therapy shows efficacy in blood cancerNature Biotechnology, 2011
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalJournal of Clinical Oncology, 2011